Polycythemia Vera (PV)

Overview

Polycythemia Vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm defined by erythrocytosis and near-universal JAK2 V617F mutation. It sits under MPN in OncoTree. PV carries the highest JAK2 mutation prevalence of the classic MPNs.

Cohorts in the corpus

• mpn_cimr_2013 — 48 PV patients with whole-exome sequencing. PMID:24325359

Recurrent alterations

• In 48 PV patients, JAK2 V617F was present in 48/48 (100%). CALR mutations were absent in all 48 PV patients, consistent with CALR being restricted to JAK2/MPL-negative ET and MF. Median 6.5 somatic mutations per patient. PMID:24325359

Subtypes

• No molecular subtypes defined in the current corpus beyond JAK2 driver.

Therapeutic landscape

• JAK2 inhibition (ruxolitinib) is standard-of-care context; no specific drug data in the current corpus. PMID:24325359

Sources

• PMID:24325359

This page was processed by crosslinker on 2026-05-09.